The Global Regulatory Paradox of Cannabis Versus Nicotine

Sun, 06 Sep 2026 00:00:00 +0000

A new Harm Reduction Journal paper by Konstantinos Farsalinos argues that global drug policy has become internally inconsistent, and the application of double standards is becoming the new “norm”.

Key Takeaways
#

Cannabis, a psychoactive substance linked to real risks of psychosis and cognitive decline, is rolling out globally under the promise of personal freedom.
At the same time, non-combustible nicotine products—like vapes, pouches, and snus, which don’t intoxicate and carry far lower toxicological risks than smoking—are getting banned or criminalized in dozens of countries.
This contradiction has been labeled a “regulatory paradox.” In both cases, it’s the combustion, not the drug itself, that drives most of the harm, yet policy treats them as opposites.
From a toxicological standpoint, smoke is smoke; cannabis smoke shares carcinogens and toxic pathways with tobacco smoke and may even deliver more tar per puff. Yet the restrictions focus on nicotine’s non-combustible forms while leaving cannabis smoking largely unchecked.
Neurocognitively, nicotine acts as a non-intoxicating stimulant with proven cognitive benefits like sharpened attention and working memory, whereas THC carries a well-documented, dose-dependent link to acute psychosis and cognitive impairment.
A double standard protecting youth runs through both markets: flavor bans and “gateway theory” fears are weaponized against vapes and pouches, while flavored, youth-appealing THC edibles and vapes proliferate with little regulatory pushback.
Sociologically, the “Iron Law of Prohibition” is playing out again: Australia’s 2024 e-cigarette restrictions coincided with an estimated 95.7% of its vape market going illicit—the same black-market dynamic regulators previously accepted as a lesson from cannabis and alcohol prohibition.
Bioethically, cannabis legalization is defended through “cognitive liberty” and adult autonomy, while nicotine regulation has swung toward “hard paternalism,” treating addiction as negating free will and denying smokers access to lower-risk substitutes. The comparison of dependence also contradicts the policy trend.
While nicotine has a higher capture rate among first-time users, cannabis use disorder is more prevalent at a population level and includes a clinically validated withdrawal syndrome, undercutting the idea that cannabis is simply the “safe” substance and nicotine the dangerous one.
Economically and in criminal-justice terms, the paper argues nicotine bans reproduce the very costs cannabis liberalization was meant to avoid: lost tax revenue, destroyed legitimate businesses, and enforcement resources funneled into policing a black market instead of advancing public health.

The Core Claim, Up Front
#

The argument is straightforward: if you separate THC and nicotine from their traditional delivery systems—smoked cannabis and combustible cigarettes—the toxicology simply doesn’t support current policy. Combustion, not the drug itself, is the primary driver of harm in both scenarios. Yet policy has moved in opposite directions: cannabis is heading toward liberalization, while nicotine is facing prohibition of exactly the products—e-cigarettes, snus, and pouches—that remove combustion from the equation.

Bioethics on Farsalinos

The Global Regulatory Paradox of Cannabis Versus Nicotine

Key Takeaways #

The Core Claim, Up Front #

Key Takeaways
#

The Core Claim, Up Front
#